DAWN (Day One Biopharmaceuticals, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by DAWN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-23 | William Grossman | Director | D | — | — |
| 2026-04-23 | Habib J Dable | Director | D | — | — |
| 2026-04-23 | Lauren Merendino | Chief Commercial Officer | D | — | — |
| 2026-04-23 | MICHAEL VASCONCELLES | Head of Research and Dev. | D | — | — |
| 2026-04-23 | J. Scott Garland | Director | D | — | — |
| 2026-04-23 | Garry A Nicholson | Director | D | — | — |
| 2026-04-23 | Adam Dubow | Gen Counsel & Secretary | D | — | — |
| 2026-04-23 | Charles N York II | COO and CFO | D | — | — |
| 2026-04-23 | Natalie C. Holles | Director | D | — | — |
| 2026-04-23 | Jeremy Bender | CHIEF EXECUTIVE OFFICER | D | — | — |
| 2026-04-23 | John A. Josey | Director | D | — | — |
| 2026-04-23 | Saira Ramasastry | Director | D | — | — |
| 2026-02-18 | Charles N York II | COO and CFO | MIXED | — | — |
| 2026-02-18 | MICHAEL VASCONCELLES | Head of Research and Dev. | MIXED | — | — |
| 2026-02-18 | Adam Dubow | Gen Counsel & Secretary | MIXED | — | — |
| 2026-02-18 | Lauren Merendino | Chief Commercial Officer | MIXED | — | — |
| 2026-02-18 | Jeremy Bender | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2026-01-30 | Charles N York II | COO and CFO | A | — | — |
| 2026-01-30 | Adam Dubow | Gen Counsel & Secretary | A | — | — |
| 2026-01-30 | Lauren Merendino | Chief Commercial Officer | A | — | — |
| 2026-01-30 | MICHAEL VASCONCELLES | Head of Research and Dev. | A | — | — |
| 2026-01-30 | Jeremy Bender | CHIEF EXECUTIVE OFFICER | A | — | — |
| 2025-11-26 | Jeremy Bender | CHIEF EXECUTIVE OFFICER | G | — | — |
| 2025-11-18 | Jeremy Bender | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2025-11-18 | Lauren Merendino | Chief Commercial Officer | MIXED | — | — |
| 2025-11-18 | Charles N York II | COO and CFO | MIXED | — | — |
| 2025-11-18 | Adam Dubow | Gen Counsel & Secretary | MIXED | — | — |
| 2025-11-07 | Adam Dubow | Gen Counsel & Secretary | MIXED | — | — |
| 2025-11-07 | John A. Josey | Director | MIXED | — | — |
| 2025-11-07 | J. Scott Garland | Director | MIXED | — | — |
| 2025-11-07 | Habib J Dable | Director | MIXED | — | — |
| 2025-11-07 | Jeremy Bender | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2025-11-07 | Natalie C. Holles | Director | MIXED | — | — |
| 2025-11-07 | Saira Ramasastry | Director | MIXED | — | — |
| 2025-11-07 | William Grossman | Director | MIXED | — | — |
| 2025-11-07 | Lauren Merendino | Chief Commercial Officer | MIXED | — | — |
| 2025-11-07 | Charles N York II | COO and CFO | MIXED | — | — |
| 2025-11-07 | Garry A Nicholson | Director | MIXED | — | — |
| 2025-08-19 | Lauren Merendino | Chief Commercial Officer | MIXED | — | — |
| 2025-08-19 | Adam Dubow | Gen Counsel & Secretary | MIXED | — | — |
| 2025-08-19 | Jeremy Bender | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2025-08-19 | Charles N York II | COO and CFO | MIXED | — | — |
| 2025-07-14 | Jeremy Bender | CHIEF EXECUTIVE OFFICER | G | — | — |
| 2025-06-18 | MICHAEL VASCONCELLES | Head of Research and Dev. | A | — | — |
| 2025-06-04 | Saira Ramasastry | Director | A | — | — |
| 2025-06-04 | J. Scott Garland | Director | A | — | — |
| 2025-06-04 | Natalie C. Holles | Director | A | — | — |
| 2025-06-04 | John A. Josey | Director | A | — | — |
| 2025-06-04 | Garry A Nicholson | Director | A | — | — |
| 2025-06-04 | Habib J Dable | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 12,817,935 | — |
| — | — | 11,453,868 | — |
| — | — | 10,684,638 | — |
| — | — | 9,377,776 | — |
| — | 10%+ Owner | 8,464,301 | — |
| — | 10%+ Owner | 7,976,909 | — |
| — | 10%+ Owner | 6,527,606 | — |
| — | 10%+ Owner | 6,230,462 | — |
| — | 10%+ Owner | 6,008,534 | — |
| — | HEAD OF R&D | 2,034,015 | — |
| — | 10%+ Owner | 793,116 | — |
| — | Director | 766,667 | — |
| — | Director | 467,358 | — |
| — | Director | 5,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the DAWN quote page; the site-wide leaderboard is on the insider transactions hub.